As of the latest Form 4 filed Jul 10, 2026.
What Mineralys Therapeutics, Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 53 most recent filings for MLYS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-10 | 2026-07-09 | Rodman David Malcom Chief Medical Officer | SSale | −2.17K | $30.30 | $65.8K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-09 | Rodman David Malcom, Chief Medical Officer | MExercise | +2.17K | $16.00 | $34.7K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | Congleton Jon Chief Executive Officer | SSale | −17.0K | $26.82 | $456K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-30 | Congleton Jon, Chief Executive Officer | SSale | −58.0K | $25.94 | $1.50M | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Warren Eric Chief Commercial Officer | SSale | −104K | $25.90 | $2.70M | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Warren Eric, Chief Commercial Officer | MExercise | +104K | $13.24 | $1.38M | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-17 | Rodman David Malcom Chief Medical Officer | SSale | −4.58K | $25.00 | $115K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-17 | Rodman David Malcom, Chief Medical Officer | MExercise | +417.00 | $15.44 | $6.44K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-17 | Rodman David Malcom, Chief Medical Officer | MExercise | +4.17K | $14.25 | $59.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-17 | Karydas Daphne Director | SSale | −3.00K | $25.00 | $75.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-17 | Karydas Daphne, Director | MExercise | +3.00K | $12.02 | $36.1K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Rodman David Malcom Chief Medical Officer | SSale | −9.89K | $23.81 | $235K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Rodman David Malcom, Chief Medical Officer | MExercise | +3.54K | $10.20 | $36.1K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-12 | Rodman David Malcom Chief Medical Officer | SSale | −6.35K | $23.93 | $152K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-12 | Rodman David Malcom, Chief Medical Officer | MExercise | +6.35K | $1.08 | $6.86K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Rodman David Malcom, Chief Medical Officer | SSale | −2.17K | $25.00 | $54.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Rodman David Malcom, Chief Medical Officer | MExercise | +2.17K | $16.00 | $34.7K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Rodman David Malcom Chief Medical Officer | SSale | −14.1K | $28.58 | $402K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +4.17K | $14.25 | $59.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +3.54K | $10.20 | $36.1K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-12 | Rodman David Malcom, Chief Medical Officer | SSale | −6.35K | $29.36 | $186K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-12 | Rodman David Malcom, Chief Medical Officer | MExercise | +6.35K | $1.08 | $6.86K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Rodman David Malcom, Chief Medical Officer | SSale | −2.17K | $29.71 | $64.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Rodman David Malcom, Chief Medical Officer | MExercise | +2.17K | $16.00 | $34.7K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Rodman David Malcom Chief Medical Officer | SSale | −416.00 | $31.33 | $13.0K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Rodman David Malcom, Chief Medical Officer | MExercise | +416.00 | $15.44 | $6.42K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Rodman David Malcom Chief Medical Officer | SSale | −6.35K | $27.66 | $176K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Rodman David Malcom, Chief Medical Officer | SSale | −14.1K | $26.54 | $373K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +4.17K | $14.25 | $59.4K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +3.54K | $10.20 | $36.1K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +6.35K | $1.08 | $6.86K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Congleton Jon Chief Executive Officer | SSale | −15.7K | $26.83 | $422K | Yes (planned) | Form 4 ↗ |
| 2026-04-13 | 2026-04-09 | Rodman David Malcom Chief Medical Officer | SSale | −2.17K | $27.38 | $59.4K | Yes (planned) | Form 4 ↗ |
| 2026-04-13 | 2026-04-09 | Rodman David Malcom, Chief Medical Officer | MExercise | +2.17K | $16.00 | $34.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-31 | 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. Director | PPurchase | +58.3K | $24.16 | $1.41M | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-27 | RA CAPITAL MANAGEMENT, L.P., Director | PPurchase | +311K | $23.67 | $7.35M | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-13 | Rodman David Malcom Chief Medical Officer | SSale | −253.00 | $27.82 | $7.04K | Yes (planned) | Form 4 ↗ |
| 2026-03-16 | 2026-03-13 | Rodman David Malcom, Chief Medical Officer | SSale | −3.08K | $27.37 | $84.3K | Yes (planned) | Form 4 ↗ |
| 2026-03-16 | 2026-03-13 | Rodman David Malcom, Chief Medical Officer | SSale | −10.7K | $25.91 | $278K | Yes (planned) | Form 4 ↗ |
| 2026-03-16 | 2026-03-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +4.17K | $14.25 | $59.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-16 | 2026-03-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +3.54K | $10.20 | $36.1K | Yes (planned) | Form 4 ↗ |
| 2026-03-16 | 2026-03-12 | Rodman David Malcom, Chief Medical Officer | SSale | −6.35K | $27.37 | $174K | Yes (planned) | Form 4 ↗ |
| 2026-03-16 | 2026-03-12 | Rodman David Malcom, Chief Medical Officer | MExercise | +6.35K | $1.08 | $6.86K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-13 | Rodman David Malcom Chief Medical Officer | SSale | −6.35K | $27.58 | $175K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-13 | Rodman David Malcom, Chief Medical Officer | SSale | −4.17K | $27.33 | $114K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +4.17K | $14.25 | $59.4K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-13 | Rodman David Malcom, Chief Medical Officer | SSale | −3.54K | $27.33 | $96.8K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-13 | Rodman David Malcom, Chief Medical Officer | MExercise | +3.54K | $10.20 | $36.1K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Rodman David Malcom, Chief Medical Officer | SSale | −521.00 | $29.64 | $15.4K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Rodman David Malcom, Chief Medical Officer | SSale | −5.83K | $28.94 | $169K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Rodman David Malcom, Chief Medical Officer | MExercise | +6.35K | $1.08 | $6.86K | Yes (planned) | Form 4 ↗ |
| 2026-02-11 | 2026-02-09 | Rodman David Malcom Chief Medical Officer | SSale | −2.17K | $30.21 | $65.6K | Yes (planned) | Form 4 ↗ |
| 2026-02-11 | 2026-02-09 | Rodman David Malcom, Chief Medical Officer | MExercise | +2.17K | $16.00 | $34.7K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also MLYS’s full analysis or the market-wide insider trading feed. The tabs above jump to MLYS’s other SEC data.
Source: SEC Form 4 filings for MLYS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.